
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is expected to face challenges in the near term from pricing pressure on its Baqsimi product and competition for its generic epinephrine and glucagon products, leading to margin erosion and lower EBITDA estimates. However, the company has a strong pipeline of generic and proprietary products that will continue to drive future success, as the development and commercialization of new products is time-consuming, costly and involves a high degree of risk. An update in the company's valuation methodology has led to a lowered price target of $21, reflecting a multiple of 7x based on the 2027E EBITDA estimate of $204M, discounted by 12% for one year.
Bears say
Amphastar Pharma is currently facing a number of challenges that are negatively impacting its financial performance and outlook. These include pricing headwinds for its flagship product Baqsimi, which has experienced significant erosion in average selling price due to higher rebates and discounts. Additionally, the company is facing competitive pressures in its base generics business, specifically in its injectable glucagon product due to the entry of a new generic competitor. Despite having a number of potential opportunities in its pipeline, the visibility into when these could materialize and contribute to top-line and EBITDA growth is unclear. As a result, the stock is fairly valued at an EV/2027E EBITDA of ~7x, leading to a negative outlook.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares